New drug therapies and their effect on the skin.
New therapeutic agents - mainly those applied in treatment of cancer and in immunologically mediated diseases - can elicit previously unknown cutaneous adverse drug reactions (ADR) and each dermatologist should be familiar with these clinical pictures. Established classification systems fail to adequately represent ADR to these new therapeutics, which often belong to the group of biological immune response modifiers. Thus, a new classification system was recently proposed for ADR to these new drugs and this paper gives an overview of typical clinical entities. The emphasis is put on ADR elicited by EGFR inhibitors and by TNF antagonists. Current strategies for management of these ADR, as well as for selected other new therapeutics and their typical ADR, are discussed.The fast development of new drugs and their wider application will undoubtedly continue to be a challenge for dermatologists.
Treudler
Regina
R
Department of Dermatology,Venerology, and Allergology, Universitätsklinikum Leipzig A.ö.R., Leipzig, Germany. regina.treudler@uniklinik-leipzig.de
D003880:Dermatology / Q000592:standards*; D003875:Drug Eruptions / Q000145:classification* / Q000209:etiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005858:Germany; D006801:Humans; D017410:Practice Guidelines as Topic; D012867:Skin / Q000187:drug effects*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D014409:Tumor Necrosis Factor-alpha; C512478:EGFR protein, human; D066246:ErbB Receptors